Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (201-210 of 250) with videos related to

Pageof 25
Sort By:
Frontiers in Immunology|February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
The New England Journal of Medicine|June 22, 2007
Natural history of multiple sclerosis with childhood onsetChristel Renoux, Sandra Vukusic, Yann Mikaeloff, et al.
Frontiers in Immunology|March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 21, 2022
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS SubstudyHeinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, et al.
Journal of Medical Internet Research|October 6, 2021
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based SurveyTjalf Ziemssen, Gavin Giovannoni, Enrique Alvarez, et al.
European Radiology|June 21, 2018
Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?Aikaterini Fitsiori, Luc-Matthieu Fornecker, Laurence Simon, et al.
Neurology and Therapy|December 23, 2022
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert ConsensusJerome De Sèze, Laurent Suchet, Claude Mekies, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2021
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing dataAlasdair J Coles, Joanne L Jones, Patrick Vermersch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2019
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studiesBart Van Wijmeersch, Barry A Singer, Aaron Boster, et al.
Plos One|January 4, 2017
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple SclerosisBruno Brochet, Mathilde S A Deloire, Paul Perez, et al.
Pageof 25

Showing results (201-210 of 250) with videos related to

Sort By:
Pageof 25
Frontiers in Immunology|February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
The New England Journal of Medicine|June 22, 2007
Natural history of multiple sclerosis with childhood onsetChristel Renoux, Sandra Vukusic, Yann Mikaeloff, et al.
Frontiers in Immunology|March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 21, 2022
Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS SubstudyHeinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, et al.
Journal of Medical Internet Research|October 6, 2021
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based SurveyTjalf Ziemssen, Gavin Giovannoni, Enrique Alvarez, et al.
European Radiology|June 21, 2018
Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?Aikaterini Fitsiori, Luc-Matthieu Fornecker, Laurence Simon, et al.
Neurology and Therapy|December 23, 2022
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert ConsensusJerome De Sèze, Laurent Suchet, Claude Mekies, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2021
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing dataAlasdair J Coles, Joanne L Jones, Patrick Vermersch, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2019
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studiesBart Van Wijmeersch, Barry A Singer, Aaron Boster, et al.
Plos One|January 4, 2017
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple SclerosisBruno Brochet, Mathilde S A Deloire, Paul Perez, et al.
Pageof 25